CELLULAR THERAPY OF CANCER WITH TUMOR PRIMED ANTI CD3 ACTIVATED LYMPHOCYTES

这是一项评估免疫T细胞有效性的研究，在实验室中生长和激活，用于治疗转移性肾细胞癌患者。 在动物研究中，免疫T细胞在荷瘤动物中的转移在引起晚期肿瘤消退方面非常有效。 在这项研究中，研究人员将通过给患者接种与细菌免疫刺激剂BCG混合的自身肿瘤细胞来评估产生免疫T细胞的能力。 这导致疫苗部位的炎症反应活跃以及邻近疫苗部位的引流淋巴结肿大。 在接种疫苗后7 - 10天内手术切除淋巴结。 然后在实验室中使用称为抗CD 3的单克隆抗体激活这些淋巴结。 这将导致淋巴结细胞被激活，并允许称为IL-2的免疫激素的扩增。 一旦这些细胞以大得多的数量生长，它们将用于输注到患者中，沿着施用IL-2以治疗残留的转移性疾病。 这是一项II期试验，将有助于确定这种疗法在IV期肾细胞癌患者中的反应率。 在实验室中测量的细胞的免疫反应性将与在患者中观察到的肿瘤反应相关。

This is a study to evaluate the effectiveness of immune T cells, grown and activated in the laboratory, to be utilized in the treatment of patients with metastatic renal cell cancer. In animal studies, the transfer of immune T cells in tumor bearing animals are highly effective in causing the regression of advanced tumors. In this study, the investigators will evaluate the ability to generate immune T cells by vaccinating patients with their own tumor cells mixed with a bacterial immune stimulating agent, BCG. This results in a brisk inflammatory response at the vaccine site as well as enlargement of draining lymph nodes adjacent to the vaccine site. The lymph nodes will be surgically removed after a 7 -10 day period from the time of the vaccine. These lymph nodes will then be activated in the laboratory utilizing a monoclonal antibody known as anti-CD3. This will cause the lymph node cells to become activated and allow expansion in an immune hormone called IL-2. Once these cells have grown in much larger numbers, they will be used for infusion into the patients along with the administration of IL-2 for the treatment of residual metastatic disease. This represents a phase II trial which will help determine what the response rate of this therapy will be in patients with stage IV renal cell carcinoma. The immunological reactivity of the cells as measured in the laboratory will be correlated with tumor responses observed in patients.